Mirum Pharmaceuticals Inc Earnings

The next earnings date for Mirum Pharmaceuticals Inc has not yet been scheduled.

Analyst Estimates of Mirum Pharmaceuticals Inc Earnings

No Results.

Report Date	Estimated Earnings Per Share
No Results.

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Mirum Pharmaceuticals Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
03/11/2026	---	$-0.12	-146.91%
11/12/2025	---	$0.05	134.20%
08/06/2025	---	$-0.12	63.64%
05/06/2025	Before Market	$-0.30	37.50%
02/26/2025	Before Market	$-0.49	-98.70%
11/04/2024	After Market	$-0.30	33.80%
08/07/2024	After Market	$-0.52	-10.64%
05/08/2024	After Market	$-0.54	-12.50%
02/28/2024	After Market	$-0.66	-175.00%
11/02/2023	After Market	$-0.57	9.52%
08/03/2023	After Market	$-1.94	-142.50%
05/04/2023	After Market	$-0.80	14.89%
03/08/2023	After Market	$-0.99	2.94%
11/09/2022	Before Market	$-1.02	4.67%
08/04/2022	After Market	$-0.84	26.96%
05/05/2022	Before Market	$-1.17	12.69%
03/09/2022	After Market	$-1.66	-574.29%
11/15/2021	After Market	$-1.55	10.40%
08/05/2021	After Market	$-1.45	-123.08%
05/06/2021	After Market	$-1.69	-144.93%
03/09/2021	After Market	$-1.43	-98.61%
11/12/2020	Before Market	$-0.86	12.24%
08/06/2020	After Market	$-0.93	-6.90%
05/07/2020	After Market	$-0.86	-4.88%
03/12/2020	After Market	$-0.79	7.06%
11/06/2019	After Market	$-0.84	-42.37%
08/28/2019	After Market	$-5.31	-831.58%
05/29/2019	---	$-0.60	---

More About Mirum Pharmaceuticals Inc

Website

https://www.mirumpharma.com

Country

USA

Full Time Employees

369

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

“Mirum Pharmaceuticals Inc Earnings” Can Refer to the Mirum Pharmaceuticals Inc Earnings Date

Some people say “Mirum Pharmaceuticals Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Mirum Pharmaceuticals Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Mirum Pharmaceuticals Inc Stock on the Earnings Date

If you own Mirum Pharmaceuticals Inc stock (MIRM) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Mirum Pharmaceuticals Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Mirum Pharmaceuticals Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Mirum Pharmaceuticals Inc Earnings

You can contact us any time if you would like to ask questions about Mirum Pharmaceuticals Inc earnings or anything else related to the stock market.